Apoptosis regulating genes in neuroendocrine tumors

Histology and Histopathology

Volumn 15, Issue 3, 2000, Pages 851-859

  Liu, W H ^a   Wang, D G ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Apoptosis; Neuroendocrine tumor; Tumorigenesis

Indexed keywords

MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; CAROTID BODY TUMOR; HUMAN; HYPOPHYSIS TUMOR; MELANOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE C MYC; PARATHYROID TUMOR; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; THYROID MEDULLARY CARCINOMA;

ANIMALS; APOPTOSIS; CARCINOMA, NEUROENDOCRINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033940303     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Apoptosis and proliferation in thyroid carcinoma: Correlation with bcl-2 and p53 protein expression.
2. Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23
3. Small cell carcinomas of the lung express the Bcl-2 protein
4. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1
5. The neurocrestopathies: A unifying concept of disease arising from neural crest maldevelopment
6. Apoptosis-related factors p53, Bcl-2, and Bax in neuroendocrine lung tumors
7. High expression of bcl-2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy
8. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavourable histology and N-myc amplification
9. No P53 mutations in neuroblastomas detected by PCR-SSCP analysis
10. Molecular cloning of the interleukin-1β converting enzyme
11. Positional cloning of the gene for multiple endocrine neoplasia 1
12. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system
13. Molecular and immunohistochemical analysis of p53 in phaeochromocytoma
14. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids
15. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1 associated and sporadic gastrinomas and pancreatic endocrine tumors
16. CDK4, a possible critical regulator of apoptosis in rat pheochromocytoma PC12 cells
17. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease
18. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease
19. Altered gene expression in neurones during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis
20. Induction of apoptosis in fibroblasts by c-myc protein
21. Regulation of apoptosis by steroid hormones
22. Cooperative interaction between c-myc and bcl-2 proto-oncogenes
23. Strong c-Jun immunoreactivity is associated with apoptotic cell death in human tumors of the central nervous system
24. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
25. A novel three-pronged approach to kill cancer cells selectively: Conconmitant viral, double suicide gene, and radiotherapy
26. Fas ligand-induced apoptosis as a mechanism of immune privilege
27. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
28. Absence of p53 point mutations in parathyroid adenoma and carcinoma
29. Overexpression and mutations of p53 in metastatic malignant melanomas
30. The C-cell parafollicular cells of the thyroid gland carcinoma
31. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
32. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death
33. C elegans cell survival gene ced-9 encodes a functional homologue of the mamalian protooncogene bcl-2
34. Somatic mutation of the MEN1 gene in parathyroid tumours
35. Molecular screening of pituitary adenomas for gene mutations and rearrangements
36. Mediation of c-Myc-induced apoptosis by p53
37. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter
38. Apoptosis induced by anticancer drugs
39. Bcl-2 is an inner mitochondria membrane protein that blocks programmed cell death
40. P53 mutations in human cancer
41. Hormonal regulation of apoptosis
42. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy
43. Relationship between blc-2 and myc gene expression in human neuroblastoma
44. Induction of apoptosis in neruroendocrine tumors of the digestive system during treatment with somatostain analogs
45. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma
46. A novel protein domain required for apoptosis. Mutation analysis of human Fas antigen
47. Detection of medullary thyroid cancer by calcitonin assay in families
48. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas
49. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation
50. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells
51. Definition and incidence of apoptosis: An historical perspective. In: Apoptosis: The molecular basis of cell death
52. Transforming growth factor β1 increases c-myc mRNA levels and induced growth inhibition and cell death of a human medullary thyroid carcinoma cell line
53. Hormonal control of programmed cell death/apoptosis
54. Bcl-2 slows in vitro breast cancer growth despiete its antiapoptotic effect
55. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death
56. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas: Comparisons with tumour cell differentiation and N-Myc protein
57. Cancer-p53, guardian of the genome
58. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice
59. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene
60. P53 gene mutations in pituitary adenomas: Rate events
61. Chemotherapy-induced apoptosis in melanoma cells is p53-dependent
62. Inhibition of drug-induced apoptosis by survival factors in PC12 cells
63. Induction of apoptic program in cell-free extracts: Requirements for DATP and cytochrome c
64. Aberrant p27kip1 expression in endocrine and other tumors
65. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors
66. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA
67. P53-depandent apoptosis modulates the cytotoxicity of anticancer agents
68. P53 status and the efficacy of cancer therapy in vivo
69. Absence of p53 gene mutations in cutaneous melanoma
70. Involvement of the pRb/p16cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
71. The protooncogene bcl-2 inhibits apoptosis in PC12 cells
72. Cell division versus cell death: A functional model of multistep neoplasia
73. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice trasgenic for the t(14;18)
74. Deregulated bcl-2-lg transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population
75. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma
76. Tumor suppresor p53 is a direct transcriptional activator of the human bax gene
77. Bcl-2 protein expression and gut meurohormonal polypeptide/amine production in colorectal carcinomas and tumor-neighboring mucosa, which closely correlate to the occurrence of tumor
78. Wild-type p53 and a temperature-sensitive mutant induce Fas/Apo-1 expression
79. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons
80. Carotid body tumours in humans: Genetics and epidemiology
81. Multiple genetic alterations in malignant metastatic insulinomas
82. The APUD system and hormone production
83. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors
84. Expression of bcl-2 gene product in neuroblastoma
85. Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell line of neural origin
86. Bcl-2 and the regulation of programmed cell death
87. The molecular mechanisms of neuronal apoptosis
88. Calcitonin gene-related peptide enhances apoptosis of thymocytes
89. High altitude hypoxia and chemodectomas
90. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma
91. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo
92. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes
93. Induction of hydrogen peroxide production and Bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells
94. Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2
95. Expression of mutant p53 in melanoma
96. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern
97. Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumours
98. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells
99. Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of the MEN 1 gene in sporadic pituitary adenomas
100. A novel domain within the 55-kd TNF receptor signals cell death
101. Expression of PRAD1/cyclin D1, retinoblasoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma
102. Apoptosis and steroid hormones
103. A novel heterodimeric cysteine protease is required for interleukin-β processing in monocytes
104. Role of apoptosis in the progression of secondary hyperparathyroidism
105. Bcl-2 expression in human melanocytes and melanocytic tumours
106. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors
107. Bcl-2 gene promotes haemopoietic cell survival and cooperaties with c-myc to immortalize pre B cells
108. Toward an understanding of the molecular mechanisms of physiological cell death
109. Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma
110. Absence of p53 gene mutations in primary neuroblastomas
111. p53 Function and dysfunction
112. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2
113. Over-expression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis
114. Expression Bcl-2 oncoprotein in human pituitary tumours: Comparison with c-Myc
115. Oncogene expression in carotid body tumours
116. Expression of the apoptosis suppressing gene bcl-2 in pheochromocytoma is associated with the expression of c-myc
117. Expression of apoptosis-suppressing gene bcl-2 in human carotid body tumours
118. Oncogene expression in gastroenteropancreatic neuroendocrine tumours. Implications for pathogenesis
119. Bcl-2 expression in neuroendocrine tumour of lung: Comparison with p53
120. Bcl-2 and c-Myc, but not Bax and p53 are expressed during human medullary thyroid tumourigenesis
121. Mechanisms of Bcl-2 protein function
122. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma
123. Apoptosis and expression of the proto-oncogenes bcl-2 and p53 and the proliferation factor Ki-67 in human medullary thyroid carcinoma
124. Detection of apoptosis cells and expression of Ki-67 antigen, bcl-2, p53 oncoproteins in human parathyroid adenoma
125. Molecular regulation of apoptosis: Genetic controls on cell death
126. C-cell hyperplasia preceding medullary thyroid carcinoma
127. Inactivation of the p53 gene is not required for tumorigensis of medulary thyroid carcinoma or phaeochromocytoma
128. Molecular thanatopsis: A discourse on the bcl-2 family and cell death
129. Role of p53 mutations in endocrine tumorigenesis: Mutation detection by polymerise chain reaction-single strand conformation polymorphism
130. Genetic mosaic analysis of ced-3 and ced-4, two genes that control programmed cell death in the nematode C. elegans
131. Mutations of the MEN1 tumor suppressor gene in pituitary tumors
132. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3